EGFR and head and neck squamous cell carcinoma: Cetuximab is an agent targeting EGFR and is currently approved for use in head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer; its combination with radiotherapy continues to be studied [120, 121].